At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 285 enrolled
Drug / intervention
Dapoxetinedrug
Likely dose
Dapoxetine 60mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Asia-Pacific Flexible Dose Study of Dapoxetine and Patient Satisfaction in Premature Ejaculation Therapy
In Brief
A Phase 3 clinical trial evaluating Dapoxetine for Sexual Dysfunction, Physiological. Completed, enrolled 285 participants across 13 sites in 3 countries.
Detailed Summary
The purpose of the study is to measure the efficacy of flexible dosing of dapoxetine in a setting similar to routine clinical practice.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSexual Dysfunction, Physiological
CountriesAustralia, South Korea, Thailand
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 2010
Enrollment StartMay 2010
Primary CompletionJun 2011
TodayJul 2026
First PostedFeb 5, 2010
Enrollment StartMay 22, 2010
Primary CompletionJun 14, 2011
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 16.4 years ago
Interventions
Dapoxetinedrug
Starting dose is one 30-mg tablet taken approximately 1-3 hours prior to sexual activity, may be increased after 4 weeks to 60mg, taken for 12 weeks. The maximum recommended dosing frequency is once every 24 hours.